profit from every R$100 of sales.
R$0R$100
Fleury
R$21.20+0.71% today
+36.1% in 1 year
1-year low R$14.451-year high R$28.20
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay R$18.81 for every R$1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Fleury sold, what it kept, and what it did with the cash.
Sales went from R$4.46 billion in 2022 to R$8.29 billion in 2025, with R$613 million of profit last year.
SalesProfit
Fleury handed back 32% of the cash it generated last year.
R$513M
Free cash flow 2025R$1.6B
Bought back its own sharesR$0
Paid as dividendsR$513M
Cash vs. debtR$22M vs. R$5.3B
Fleury vs. similar companies
Fleury grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from R$100 of sales | Sales growth a year | Price per R$1 of profit |
|---|---|---|---|
| Fleury | 18.8× · Fair price | ||
 Thermo Fisher Scientific | 38.7× · Expensive | ||
 Danaher | 45.4× · Expensive | ||
 Waters | 140.8× · Very expensive | ||
 WuXi AppTec | 25.8× · Fair price |
AI analysis
An AI analyst reads Fleury's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of BRL | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 4,463 | 6,471 | 7,685 | 8,291 | |
| 1,210 | 1,740 | 2,143 | 2,206 | |
| 766 | 993 | 1,232 | 1,241 | |
| 1,274 | 1,684 | 2,112 | 2,377 | |
| 308 | 424 | 616 | 613 | |
| 0.95 | 0.87 | 1.13 | 1.12 | |
| 27.1% | 26.9% | 27.9% | 26.6% | |
| 17.2% | 15.4% | 16.0% | 15.0% | |
| 6.9% | 6.5% | 8.0% | 7.4% |
Balance sheet
| In millions of BRL | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 7,792 | 11,580 | 13,062 | 13,220 |
| Cash | 17 | 22 | 22 | 22 |
| Total debt | 3,678 | 4,241 | 5,392 | 5,271 |
| Total liabilities | 5,091 | 6,469 | 7,688 | 8,124 |
| 2,682 | 5,083 | 5,289 | 5,001 | |
| 323 | 484 | 545 | 545 | |
| 8.5% | 7.1% | 8.2% | 9.5% | |
| 11.5% | 8.3% | 11.6% | 12.3% |
Cash flow
| In millions of BRL | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 987 | 1,439 | 1,930 | 2,134 | |
| 413 | 414 | 488 | 506 | |
| 574 | 1,025 | 1,442 | 1,628 | |
| Dividends paid | 337 | 510 | 343 | 513 |
| 0 | 19 | 21 | 0 | |
| 16 | 18 | 22 | 29 |
Valuation
- 18.8×
- –
- 3.42
- 1.6×
- 1.4×
- 7.1×
- 7.1×
- 14.1%
- 5.3%
- 4.5%
Profitability
- 26.6%
- 15.0%
- 7.4%
- –
- 9.5%
- 8.3%
- –
- –
- –
- –
Growth
- +22.9%
- +5.5%
- –
- –
- +19.1%
Financial health
- 2.2×
- 1.05
- –
- 2.0×
- 1.97
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 31%of 946
Top 35%of 872
Top 28%of 564
Top 25%of 867
Top 4%of 986
4.5%of the share price, paid each year
On $1,000 invested$45a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
83.7% of its profit
Room to growStretchedMore than it earns: 31.5%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
55No pass
Benjamin Graham
66Pass
Philip Fisher
45No pass
Peter Lynch
31No pass
Joel Greenblatt
41No pass
Charlie Munger
32No pass
Terry Smith
41No pass
Questions about Fleury
Is Fleury a good stock to buy?
A business with weak numbers at a fair price. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Fleury AI analysis
What does Fleury do?
Fleury S.A., together with its subsidiaries, provides diagnostic imaging, clinical analysis, fertility, and infusions services in Brazil. It operates in two segments, Diagnostic Medicine and Integrated Medicine. It is in Diagnostics & Research, based in São Paulo, SP, Brazil, with 29,000 employees.
Does Fleury pay a dividend?
Yes. At today's price the dividend is 4.5% a year, about 84% of its yearly profit. In 2025 it paid out R$513 million in dividends.
Is Fleury stock halal?
No. Fleury does not pass our halal screen: its debt is 46% of its market value, at or above the 33% limit. How we check
How has Fleury stock done over the past year?
Up 36.1% over the past twelve months, to R$21.20. It traded between R$14.45 and R$28.20 and is 24.8% below its high.
Who are Fleury's competitors?
The largest listed companies in the same industry are Thermo Fisher Scientific, Danaher, Waters and WuXi AppTec. The peers table on this page compares their profit, growth and price with Fleury's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.